The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Treating patients with NSCLC who relapse on osimertinib-based therapies
Sanjay Popat, MBBS, FRCP, PhD, Royal Marsden Hospital, London, UK, comments on the treatment options for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have relapsed on osimertinib monotherapy. Patients on the FLAURA2 (NCT04035486) regime of chemotherapy with osimertinib or receiving amivantamab plus lazertinib may benefit from a platinum doublet-based option, as they have not received platinum doublet chemotherapy. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that remains still a question unanswered. We have lots of data on patients relapsing on osimertinib monotherapy, where we have treatment options coming through. However, we don’t really understand the best treatment options for patients either on the FLAURA 2 regime of chemotherapy with osimertinib or amivantamab with lazertinib because these patients are relatively new and have been therefore excluded from the ongoing trials...
I think that remains still a question unanswered. We have lots of data on patients relapsing on osimertinib monotherapy, where we have treatment options coming through. However, we don’t really understand the best treatment options for patients either on the FLAURA 2 regime of chemotherapy with osimertinib or amivantamab with lazertinib because these patients are relatively new and have been therefore excluded from the ongoing trials. So one thing I will say is that amivantamab lazertinib is a chemo-free regime, so these patients have not experienced platinum doublet chemotherapy at all, and so you know I think it’s very reasonable for those patients to have a platinum doublet-based option, and you know there are several options for what patients might receive thereafter, depending on extrapolation of data to this group of patients for whom we don’t have a direct data set to discuss. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
